Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P11912
UPID:
CD79A_HUMAN
Alternative names:
Ig-alpha; MB-1 membrane glycoprotein; Membrane-bound immunoglobulin-associated protein; Surface IgM-associated protein
Alternative UPACC:
P11912; A0N775; Q53FB8
Background:
The B-cell antigen receptor complex-associated protein alpha chain, known as Ig-alpha, plays a pivotal role in B-cell development and antigen presentation. It is essential for the signal transduction cascade initiated by the B-cell antigen receptor complex, influencing internalization and antigen processing. Ig-alpha's interactions enhance the activity of Src-family tyrosine kinases and are crucial for BCR signaling and B-cell maturation.
Therapeutic significance:
Agammaglobulinemia 3, an autosomal recessive condition characterized by severe infections due to low B-cells and antibodies, is linked to mutations in Ig-alpha. Understanding Ig-alpha's role could lead to novel treatments for this immunodeficiency, highlighting its therapeutic significance.